EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence

C Méndez-Vidal, M Fernández-Sánchez, M Domínguez-Moreno, L García-Díaz, J Dopazo, G Antiñolo

Frontiers in Reproductive Health · 26.02.2026 · 8

DOI: 10.3389/frph.2026.1787867 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Reproductive Health, online erschienen am 26.02.2026. Verfasst von C Méndez-Vidal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Consejería de Salud y Familias, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Advanced maternal age (AMA) and assisted reproductive technologies (ART) are becoming more common and are linked with higher obstetric and perinatal risks. Genomic tools and real-world data (RWD) are transforming risk prediction and care strategies, yet their application to the AMA + ART setting remains uneven.

Objective

To synthesize recent evidence on risks associated with AMA and ART, incorporate insights from reproductive genomics and RWD, and discuss their implications for clinical care and guideline development.

Methods

Narrative review of cohort studies, systematic reviews, and meta-analyses, supplemented by focused analyses of genomic approaches: expanded carrier screening, clinical exome sequencing, preimplantation genetic testing for monogenic disorders (PGT-M) and aneuploidy (PGT-A), emerging non-invasive PGT, and pharmacogenomics, as well as RWD infrastructures such as registries, EHR datasets, and trusted research environments.

Results

Maternal age (≥40 years) increases miscarriage, gestational diabetes, hypertensive disorders, placental abnormalities, cesarean delivery, preterm birth, stillbirth, and NICU admissions. ART independently raises risks of preeclampsia, placenta previa, preterm birth, low birthweight, cesarean delivery, and neonatal complications, including in singleton. Combined AMA + ART may produce additive or synergistic effects. Donor oocytes reduces miscarriage risk but may elevate preeclampsia risk via immunologic mechanisms. Genomic technologies enable the identification of infertility-related variants, prevention of genetic conditions, individualized ovarian stimulation, and AI-assisted embryo selection. RWD enhances evidence by capturing diverse populations, supporting comparative and long-term analyses.

Conclusions

Pregnancies from AMA + ART should be managed as high risk. Integration of genomics technologies and RWD can support predictive, personalized care and inform urgently needed consensus guidelines

Schlagwörter

Stichwörter der Autor:innen

advanced maternal ageassisted reproductive technologiesin vitrofertilizationoutcomesreal-world evidencereproductive genomics

Autor:innen und Institutionen

  • Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
  • Centre for Biomedical Network Research on Rare Diseases (CIBERER), Seville, Spain.
  • VIDA Recoletas, Seville, Spain.
  • Department of Surgery, University of Seville, Seville, Spain.
  • Department of Materno-Fetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
  • Andalusian Platform for Computational Medicine, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.

Förderung

  • Ministerio de Ciencia e Innovación
  • Consejería de Salud y Familias, Junta de Andalucía

Zitieren

APA

Méndez-Vidal, C., Fernández-Sánchez, M., Domínguez-Moreno, M., García-Díaz, L., Dopazo, J., & Antiñolo, G. (2026). Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence. Frontiers in Reproductive Health, 8. https://doi.org/10.3389/frph.2026.1787867

Vancouver

Méndez-Vidal C, Fernández-Sánchez M, Domínguez-Moreno M, García-Díaz L, Dopazo J, Antiñolo G. Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence. Frontiers in Reproductive Health. 2026;8. doi:10.3389/frph.2026.1787867

BibTeX
@article{MndezVidal2026,
  author = {Méndez-Vidal, C and Fernández-Sánchez, M and Domínguez-Moreno, M and García-Díaz, L and Dopazo, J and Antiñolo, G},
  title = {Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence},
  journal = {Frontiers in Reproductive Health},
  year = {2026},
  volume = {8},
  doi = {10.3389/frph.2026.1787867}
}
Kostenlos starten →